The Motivational Enhancement Therapy and Cognitive Behavioral Therapy Supplement - Services, U. S. Department of Health and
25,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
13 °P sammeln
  • Broschiertes Buch

This manual, a supplement to Motivational Enhancement Therapy and Cognitive Behavioral Therapy for Adolescent Cannabis Users: 5 Sessions, Cannabis Youth Treatment (CYT) Series, Volume 1, presents a seven-session cognitive behavioral treatment (CBT7) approach designed especially for adolescent cannabis users. It addresses the implementation and evaluation of cognitive behavioral treatment for adolescent marijuana users as part of the Cannabis Youth Treatment Project: A Cooperative Agreement for Evaluating the Efficacy of Five Treatments for Adolescents With Self-Reported Marijuana Use and…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This manual, a supplement to Motivational Enhancement Therapy and Cognitive Behavioral Therapy for Adolescent Cannabis Users: 5 Sessions, Cannabis Youth Treatment (CYT) Series, Volume 1, presents a seven-session cognitive behavioral treatment (CBT7) approach designed especially for adolescent cannabis users. It addresses the implementation and evaluation of cognitive behavioral treatment for adolescent marijuana users as part of the Cannabis Youth Treatment Project: A Cooperative Agreement for Evaluating the Efficacy of Five Treatments for Adolescents With Self-Reported Marijuana Use and Problems Associated With Its Use. This volume provides instructions for sessions 6 through 12 of the cognitive behavioral therapy (CBT) for adolescent marijuana users. The first five sessions (two motivational enhancement therapy [MET] sessions and three CBT sessions) are described in Motivational Enhancement Therapy and Cognitive Behavioral Therapy for Adolescent Cannabis Users: 5 Sessions, CYT Series, Volume 1.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
TIP 63 Update--- To ensure that the content of this TIP is as up to date and as useful to readers as possible, SAMHSA, in January 2020, revised certain areas of all five parts. These changes will help provide readers with the latest information needed to understand medications for opioid use disorder. These changes included the following: . Updating statistics from SAMHSA, the Centers for Disease Control and Prevention, and other health authorities on opioid-related deaths, overdoses, accidents, and hospitalizations. . Updating the expanded list of other qualifying practitioners who are eligible to apply for a waiver to prescribe buprenorphine (i.e., clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives). . Clarifying that buprenorphine is available in an extended-release injection formulation. . Adding information about the use of subdermal formulations of buprenorphine (i.e., Probuphine and Sublocade). . Adding information about possible clinical interactions between formulations of buprenorphine and naltrexone with various other medications and products. . Improving the language to make clear the importance of testing for HIV and hepatitis C. . Updating recommendations from the U.S. Preventive Services Task Force on performing drug screening for adults in primary care settings. . Removing or replacing broken hyperlinks to online resources.